Cargando…
Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going
Lymphangioleiomyomatosis (LAM), a multisystem disease affecting predominantly premenopausal and middle-aged women, causes progressive respiratory failure due to cystic lung destruction and is associated with lymphatic and kidney tumors. In the past, the treatment of LAM comprised exclusively anti-es...
Autores principales: | Taveira-DaSilva, Angelo M, Steagall, Wendy K, Moss, Joel |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medicine Reports
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948329/ https://www.ncbi.nlm.nih.gov/pubmed/20948684 http://dx.doi.org/10.3410/M1-93 |
Ejemplares similares
-
Management of lymphangioleiomyomatosis
por: Taveira-DaSilva, Angelo M., et al.
Publicado: (2014) -
Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis
por: Taveira-DaSilva, Angelo M, et al.
Publicado: (2015) -
Where We Are and Where We Are Going in Nut Research
por: Salas-Salvadó, Jordi, et al.
Publicado: (2023) -
The Clusmy Child: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2003) -
European HEPnet: where we are and where we are going
por: Carpenter, B E, et al.
Publicado: (1990)